Hastanelerde Karbapeneme Dirençli Gram Negatif Bakteri Enfeksiyonlarının Kontrolü

Öz

Çok ilaca dirençli gram negatif bakteri enfeksiyonları tüm dünyada büyük bir sorun olarak her geçen gün önemini artırmaktadır. Karbapenem dirençli enfeksiyonlarda, tedavi seçenekleri sınırlı kaldığından, mortalite ve morbidite yüksek seyretmektedir. Hastanelerde enfeksiyon kontrol uygulamaları ile karbapenem dirençli mikroorganizmaların yayılımının önlenmesi, bu enfeksiyonların yönetiminde önemli bir basamaktır. Bu makalede, karbapenem dirençli gram negatif bakterilerin kontrolü için hastanelerde alınacak önlemler derlenmiştir.

Anahtar Kelimeler

• karbapenem direnci
• gram negatif bakteri
• enfeksiyon kontrol önlemleri

Kaynakça

1. 1. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682-707.
2. 2. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O,Maor Y, et al. Outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18:54–60.
3. 3. World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug resistant bacterial infections, including tuberculosis. 2017. Available at: http://www.who.int/medicines/ areas/rational_use/prioritization-of-pathogens/en/. Accessed January 2017.
4. 4. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014; 20:1170–5.
5. 5. Zhang Y, Chen XL, Huang AW, Liu SL, Liu WJ, Zhang N, et al. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Emerg Microbes Infect. 2016; 5:e27.
6. 6. Lemos EV, de la Hoz FP, Einarson TR, McGhan WF, Quevedo E, Castañeda C,et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect. 2014; 20:416–23.
7. 7. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al.; European Society of Clinical Microbiology. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014; 20(Suppl 1):1–55.
8. 8. World Health Organization. Guidelines for the prevention and control of carbapenem- resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. 2017. Available at: http://www.who.int/infection- prevention/publications/guidelines-cre/en/. Accessed June 2018.

9. 9. Otter JA, Mutters NT, Tacconelli E, Gikas A, Holmes AH. Controversies in guidelines for the control of multidrug-resistant Gram-negative bacteria in EU countries. Clin Microbiol Infect. 2015; 21:1057–66.
10. 10. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8:336–41.
11. 11. Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control. 2007(35): S65–S164.
12. 12. WHO guidelines on hand hygiene in health care. World Health Organization website. http://apps.who.int/iris/bitstream/10665/ 44102/1/9789241597906_eng.pdf. Accessed January 21, 2017.
13. 13. Cochard H, Aubier B, Quentin R, van der Mee-Marquet N. Extended-spectrum β-lactamase-producing Enterobacteriaceae in French nursing homes: an association between high carriage rate among residents, environmental contamination, poor conformity with good hygiene practice, and putative residentto- resident transmission. Infect Control Hosp Epidemiol. 2014;35:384–389.
14. 14. Weber DJ, Rutala WA, Kanamori H, Gergen MF, Sickbert- Bennett EE. Carbapenem-Resistant Enterobacteriaceae: frequency of hospital room contamination and survival on various inoculated surfaces. Infect Control Hosp Epidemiol. 2015;36: 590–593.
15. 15. Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis. 2002;8:881–890.
16. 16. 126. de Jager P, Chirwa T, Naidoo S, Perovic O, Thomas J. Nosocomial outbreak of New Delhi metallo-β-lactamase-1-producing Gram-negative bacteria in South Africa: a casecontrol study. PloS One. 2015;10:e0123337.
17. 17. Reichel M, Schlicht A, Ostermeyer C, Kampf G. Efficacy of surface disinfectant cleaners against emerging highly resistant Gram-negative bacteria. BMC Infect Dis. 2014;14:292.
18. 18. Ben-David D, Masarwa S, Adler A, Mishali H, Carmeli Y, Schwaber MJ. A national intervention to prevent the spread of carbapenem-resistant Enterobacteriaceae in Israeli post-acute care hospitals. Infect Control Hosp Epidemiol. 2014;35:802–809.
19. 19. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011; 11:355–362.
20. 20. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase producing Gram-negative bacteria. Clin Micro Infect. 2012;18: 439–448.